Data Insights

Cabozantinib s-malate by Exelixis for Soft Tissue Sarcoma: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Soft Tissue Sarcoma

Data Insights

Cabozantinib s-malate by Exelixis for Osteosarcoma: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Osteosarcoma

Data Insights

Cabozantinib s-malate by Exelixis for Endometrial Cancer: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Endometrial Cancer

Data Insights

Cabozantinib s-malate by Exelixis for Metastatic Melanoma: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Metastatic Melanoma

Data Insights

Cabozantinib s-malate by Exelixis for Pheochromocytoma: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Pheochromocytoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Pheochromocytoma

Data Insights

Cabozantinib s-malate by Exelixis for Melanoma: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase I for Melanoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Melanoma

Data Insights

Cabozantinib s-malate by Exelixis for Colorectal Cancer: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Colorectal Cancer

Data Insights

Zanzalintinib fumarate by Exelixis for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Oral Cavity (Mouth) Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Zanzalintinib Fumarate in Oral Cavity (Mouth) Cancer

Data Insights

Zanzalintinib fumarate by Exelixis for Oropharyngeal Cancer: Likelihood of Approval

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Zanzalintinib Fumarate in Oropharyngeal Cancer

Data Insights

Zanzalintinib fumarate by Exelixis for Laryngeal Cancer: Likelihood of Approval

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Laryngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Zanzalintinib Fumarate in Laryngeal Cancer

Data Insights

Zanzalintinib fumarate by Exelixis for Hypopharyngeal Cancer: Likelihood of Approval

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Hypopharyngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Zanzalintinib Fumarate in Hypopharyngeal Cancer

Data Insights

Cabozantinib s-malate by Exelixis for Esophageal Cancer: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Esophageal Cancer

Data Insights

Cabometyx by Exelixis for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval

Cabometyx is under clinical development by Exelixis and currently in Pre-Registration for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to GlobalData, Pre-Registration...

Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)

Data Insights

Cabozantinib s-malate by Exelixis for Penile Cancer: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Penile Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Penile Cancer

Data Insights

Zanzalintinib fumarate by Exelixis for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Oral Cavity (Mouth) Cancer. According to...

Data Insights

Zanzalintinib fumarate by Exelixis for Oropharyngeal Cancer: Likelihood of Approval

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase...

Data Insights

Zanzalintinib fumarate by Exelixis for Laryngeal Cancer: Likelihood of Approval

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Laryngeal Cancer. According to GlobalData, Phase...

Data Insights

Zanzalintinib fumarate by Exelixis for Hypopharyngeal Cancer: Likelihood of Approval

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Hypopharyngeal Cancer. According to GlobalData, Phase...

Data Insights

Cabozantinib s-malate by Exelixis for Esophageal Cancer: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...

Data Insights

Cabozantinib s-malate by Exelixis for Penile Cancer: Likelihood of Approval

Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Penile Cancer. According to GlobalData, Phase...